While companies may spend a lot of time testing models before launch, many spend too little time considering how they will work in wild. In particular, they fail to fully consider how rates of adoption can warp developers’ intent.
Are you concerned about the devastating impact of climate change? Take a closer look at your toilet paper. And no, you don’t have to stop wiping.
Desk jobs just don’t deliver a sense of accomplishment. Here’s how LEGO sets can make your workday more productive.
This year has already witnessed a handful of memorable FDA approvals. But the race isn’t over yet. Looking to close out 2021 with FDA approvals stand four potential blockbusters from the likes of Argenx, UCB, Pfizer and Roche, according to Evaluate Pharma. Those meds combined are worth roughly $7.1 billion in sales cumulatively by 2026, according to Evaluate’s estimates.
Getting started is often the most difficult part—and that’s especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their diagnosis starting point. For Horizon Therapeutics’ first innovation challenge, it took that struggle to heart and asked for technology-based rare disease solutions that result in faster or more accurate diagnoses.
